Metformin-induced thyrotropin suppression is not associated with cardiac effects

Hormones

Volumn 13, Issue 2, 2014, Pages 252-258

  Cappelli, Carlo ^a   Rotondi, Mario ^b   Pirola, Ilenia ^a   Agosti, Barbara ^c   Formenti, Ana Maria ^a   De Cata, Pasquale ^b   Salvetti, Massimo ^a   Chiovato, Luca ^b   Castellano, Maurizio ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c SPEDALI CIVILI   (Italy)

Author keywords

Atrial fibrillation; Metformin; Sub clinical hyperthyroidism

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; LIOTHYRONINE; METFORMIN; THYROTROPIN; THYROXINE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ELECTROCARDIOGRAPHY; EUTHYROIDISM; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HEART RATE; HEART RATE VARIABILITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; P WAVE; P WAVE DISPERSION; P WAVE DURATION; QT DISPERSION; QT INTERVAL; RETROSPECTIVE STUDY; SUBCLINICAL HYPERTHYROIDISM; SYSTOLIC BLOOD PRESSURE; THYROID DISEASE; THYROTROPIN BLOOD LEVEL; BLOOD; DIABETES MELLITUS, TYPE 2; DOWN REGULATION; DRUG EFFECTS; MIDDLE AGED; RISK ASSESSMENT; TIME;

BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK ASSESSMENT; THYROTROPIN; TIME FACTORS;

EID: 84899646067     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401339     Document Type: Article

References (37)

1. DeFronzo RA, Goodman AM, 1995 Efficacy of metformin in patients with non insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Eng J Med 333: 541.
2. UK Prospective Diabetes Study (UKPDS) Group, 1998 Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854.
3. Abdelghaffar S, Attia A, 2009 Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. Coch Data Sys Rev 21: CD006691.
4. Scheen AJ, 2005 Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf 28: 601-631.
5. Stocker DJ, Vigersky RA, Stocker DJ, 2005 The effects of metformin and rosiglitazone on vitamin B12, folate and homocysteine in patients with poorly controlled type 2 diabetes. Abstract book of the 87th Annual Meeting of The Endocrine Society; Abstract P3: 604-693.
6. Vigersky RA, Filmore-Nassar A, Glass AR, 2006 Thyreotropin suppression by metformin. J Clin Endocrinol Metab 91: 225-227.
7. Isidro ML, Penìn MA, Nemina R, Cordida F, 2007 Metformin reduces thyrotropin levels in obese, diabetic women with primary hypothyroidism on thyroidism on thyroxine replacement therapy. Endocrine 32: 79-82.
8. Cappelli C, Rotondi M, Pirola I, et al, 2009 TSH-lowering effect of metformin in type 2 patients with diabetes. Diabetes Care 32: 1589-1590.
9. Morteza Taghavi S, Rokni H, Fatemi S, 2011 Metformin decreases thyrotropin in overweight women with polycystic ovarian syndrome and hypothyroidism. Diab Vasc Dis Res 8: 47-48.
10. Rotondi M, Cappelli C, Magri F, et al, 2011 Thyroidal effect of metformin treatment in patients with polycystic ovary syndrome. Clin Endocrinol 75: 378-381.
11. Pappa T, Alevizaki M, 2013 Metformin and thyroid: an update. Eur Thyroid J 2: 22-28.
12. Portella RB, Pedrosa RC, Coeli CM, Buescu A, Vaisman M, 2007 Altered cardiovascular vagal responses in nonelderly female patients with subclinical hyperthyroidism and no apparent cardiovascular disease. Clin Endocrinol 67: 290-294.
13. Petretta M, Bonaduce D, Spinelli L, et al, 2001 Cardiovascular haemodynamics and cardiac autonomic control in patients with subclinical and overt hyperthyroidism. Eur J Endocrinol 145: 691-696.
14. Collet TH, Gussekloo J, Bauer DC, et al, 2012 Thyroid Studies Collaboration. Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 172: 799-809.
15. Kikuya M, Hozawa A, Ohokubo T, et al, 2000 Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension 36: 901-906.
16. Shah S, Kambur T, Chan C, et al, 2013 Relation of short-term heart rate variability to incident heart failure (from the multi-Ethnic study of atherosclerosis). Am J Cardiol 112: 533-540.
17. Galetta F, Franzoni F, Fallahi P, et al, 2009 Changes in autonomic regulation and ventricular repolarization induced by subclinical hyperthyroidism. Biomed Pharmacoter 64: 546-549.
18. Owecki M, Michalak A, Nikisch E, Sowiński J, 2006 Prolonged ventricular repolarization measured by corrected QT interval (QTc) in subclinical hyperthyroidism. Horm Metab Res 38: 44-47.
19. Smit JW, Eustatia-Rutten CF, Corssmit EP, et al, 2005 Reversible diastolic dysfunction after long-term exogenous subclinical hyperthyroidism: a randomized, placebo-controlled study. J Clin Endocrinol Metab 90: 6041-6047.
20. Díez JJ, Iglesias P, 2013 Relationship between serum thyrotropin concentrations and metformin therapy in euthyroid patients with type 2 diabetes. Clin Endocrinol 78: 505-511.
21. Cappelli C, Rotondi M, Pirola I, et al, 2012 Thyreotropin levels in patients with diabetes on metformin treatment. Eur J Endocrinol 167: 261-265.
22. Alevizaki M, 2013 Metformin and thyroid: some questions still remain. Clin Endocrinol 78: 503-504.
23. Biondi B, Cooper DS, 2012 The clinical significance of subclinical thyroid dysfunction. Endocr Rev 29: 76-131.
24. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA, 2001 Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358: 861-865.
25. Iervasi G, Molinaro S, Landi P, et al, 2007 Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med 167: 1526-1532.
26. Sawin CT, Geller A, Wolf PA, 1994 Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Eng J Med 331: 1249-1252.
27. Cappola AR, Fried LP, Arnold AM, et al, 2006 Thyroid status, cardiovascular risk, and mortality in older adults. JAMA, 295: 1033-1041.
28. Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B, 2001 Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J 142: 838-842.
29. Cooper DS, Biondi B, 2012. Subclinical thyroid disease. Lancet 379: 1142-1154.
30. Gen R, Akbay E, Camsari A, Ozcan T, 2010 P-wave dispersion in endogenous and exogenous subclinical hyperthyroidism. J Endocrinol Invest 33: 88-91.
31. Vadiveloo T, Donnan PT, Cochrane L, Leese GP, 2011 The thyroid epidemiology, audit, and research study (TEARS) morbidity in patients with endogenous subclinical hyperthyroidism. J Clin Endocrinol Metab 96: 1344-1351.
32. Ceresini G, Lauretani F, Maggio M, et al, 2009 Thyroid function abnormalities and cognitive impairment in elderly people: results of the Invecchiare in Chianti study. J AM Geriatr Soc 57: 89-93.
33. Collet TH, Gussekloo J, Bauer DC, et al, 2012 Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. Arch Intern Med 172: 799-809.
34. Sgarbi JA, Matsumurs LK, Kasamatsu, et al, 2010 Subclinical thyroid dysfunctions are independent risk factors for mortality in a 7.5-year follow-up: the Japanese-Brazilian thyroid study. Eur J Endocrinol 162: 569-577.
35. Duntas LH, Orgiazzi J, Brabant G, 2011 The interface between thyroid and diabetes mellitus. Clin Endocrinol 75: 1-9.
36. Lim CT, Kola B, Korbonits M, 2010 AMPK as a mediator of hormonal signalling. J Mol Endocrinol 44: 87-97.
37. Lòpez M, Varela L, Vàzquez MJ, et al, 2010 Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat Med 16: 1001-1008.